{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1131.18","meta":{"versionId":"5","lastUpdated":"2020-11-11T01:00:26.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1131.18","version":"20201111","name":"Genomic Sequence Analysis Panel_ALK","status":"active","date":"2020-11-11T01:00:26-05:00","publisher":"CAP Steward","compose":{"include":[{"system":"http://www.ama-assn.org/go/cpt","version":"2021","concept":[{"code":"81445","display":"Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed"},{"code":"81455","display":"Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA analysis, and RNA analysis when performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed"}]}]}}